Evaxion A/S (EVAX) drops 15.56% for September 14

Equities Staff  |

Evaxion Biotech A/S - ADR (NASDAQ: EVAX) dropped to close at $7.60 Tuesday after losing $1.4 (15.56%) on volume of 55,389 shares. The stock ranged from a high of $8.99 to a low of $7.52 while Evaxion A/S’s market cap now stands at $145,909,877.

About Evaxion Biotech A/S - ADR

Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus. or MRSA) induced skin and soft tissue infections.

Visit Evaxion Biotech A/S - ADR’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Evaxion Biotech A/S - ADR and to follow the company’s latest updates, you can visit the company’s profile page here: Evaxion Biotech A/S - ADR’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

FAA Urges Airlines To Take Stronger Action With Unruly, Disruptive Passengers
Freshworks Leaps 32% on First Day of Trading After Pricing Above Filing Range
Twitter Settles Class Action for $809.5 Million Over Providing Misleading Information to Investors
DoorDash Adds Alcohol Delivery in 20 US States, DC, Canada, Australia
Bill Gates Raises More Than $1 Billion for Clean Energy Technology
CVS Health To Hire 25,000 in Virtual Career Event Friday September 24
President Biden's New Alliance With Australia and Britain Angers France and European Union
California Governor Newsom Signs Affordable Housing Law



Market Movers

Sponsored Financial Content